Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the ability of once-daily (QD) treatment with dexlansoprazole modified release (MR) 30 mg and 60 mg or placebo in maintaining healing of erosive esophagitis (EE).


Clinical Trial Description

This is a Phase 3, randomized, double-blind, multicenter, placebo-controlled, 6 month maintenance study. The study is designed to compare the efficacy and safety of daily dexlansoprazole MR (30 mg and 60 mg) with that of placebo, in maintaining healing of EE. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00321737
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date May 2006
Completion date May 2007

See also
  Status Clinical Trial Phase
Completed NCT02463643 - To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis Phase 2
Completed NCT00255151 - Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis Phase 3
Completed NCT00255164 - Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis Phase 3
Suspended NCT00282555 - Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis Phase 2
Completed NCT00251693 - Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Phase 3
Completed NCT00251719 - Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Phase 3
Not yet recruiting NCT05418920 - Clinical Trial of Reconstruction After Proximal Gastrectomy N/A
Recruiting NCT02049723 - Assessment of GERD Knowledge Level Among Patients With it in Korea N/A